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Pressure overload diseases, such as valvular stenosis
and systemic hypertension, manifest morphologically in
patients as cardiac concentric hypertrophy. Prevention of
cardiac remodeling due to increased pressure overload
is important to reduce morbidity and mortality.
Epigallocatechin-3 gallate (EGCG) is a major bioactive
polyphenol present in green tea which has been found
to be a nitric oxide-mediated vasorelaxant and to be
cardioprotective in myocardial ischemia-reperfusion
injury. Therefore, we investigated whether EGCG
supplementation could reduce in vivo pressure overload-
mediated cardiac hypertrophy. Cardiac hypertrophy was
induced by suprarenal transverse abdominal aortic
constriction (AC) in rats. Three weeks after AC surgery,
heart to body weight ratio increased in the AC group by
34% compared to the sham group. EGCG administration
suppressed the load-induced increase in heart weight by
69%. Attenuation of cardiac hypertrophy by EGCG was
associated with attenuation of the increase in myocyte cell
size and fibrosis induced by aortic constriction. Despite
abolition of hypertrophy by EGCG, transstenotic pressure
gradients did not change. Echocardiogram revealed that
increased left ventricular systolic dimensions and
deteriorated systolic function were relieved by EGCG.
These results suggest that EGCG prevents the development
of left ventricular concentric hypertrophy by pressure
overload and may be a useful therapeutic modality to
prevent cardiac remodeling in patients with pressure
overload myocardial diseases.
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Introduction
Increased cardiovascular mortality is a serious problem in
modern societies. Minimizing the risk of cardiac disease and
alleviating the complications of cardiovascular dysfunction
are the main therapeutic aims in modern medicine. Most
heart diseases, regardless of etiology or pathogenesis,
progress to congestive heart failure causing mortality [17].
The prognosis for patients with heart failure depends on the
severity of cardiac dysfunction and the presence of
complications and generally varies from guarded to poor.
The single most powerful predictor for the development of
heart failure is the presence of cardiac hypertrophy [18].
Cardiac concentric hypertrophy is a homeostatic response
to elevated afterload that develops due to pressure overload
(e.g. systemic hypertension or valvular stenosis). Although
cardiac hypertrophy is the initial compensatory response to
increased wall stress, it is followed by decompensating
hypertrophy and ultimately leads to heart failure if the
stimulus is sufficiently intense and prolonged. Cardiac
concentric hypertrophy stimulated by an increase in blood
pressure and wall stress is thought to be regulated by a
number of intracellular signal transduction pathways
including mitogen-activated protein kinase (MAPK), Janus
kinase/signal transducers, activators of transcription (JAK/
STAT), calcineurin, serine/threonine kinase, Akt and its
downstream target, glycogen synthase kinase-3β [21].
Neurohormonal factors such as angiotensin II (Ang II) and
endothelin-1 are activators of MAPK during conditions of
pathological hypertrophy [27,29]. These observations have
led to speculation that inhibition of these hypertrophic
signals may provide effective clinical therapy for pathological
hypertrophy and heart failure.
Based on considerable evidence accumulated during the
last few years, much attention is focused on the use of
naturally occurring botanicals for the prevention of many
diseases. Epidemiological studies have shown a significant
inverse association between dietary flavonoids and long-term
mortality from coronary heart disease [5]. Epigallocatechin-
3 gallate (EGCG), the major catechin derived from green
tea, has been found to have protective effects on the
cardiovascular system. These include anti-inflammatory
effects [10], lowering of serum cholesterol levels, and
reducing atherosclerosis [4]. The antioxidant properties of
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EGCG are well known [15] and have attracted considerable
attention for the prevention of oxidative stress-related
diseases such as ischemic heart diseases. The finding that
reactive oxygen radicals significantly contribute to the
genesis of reperfusion-induced dysrhythmias, contractile
malfunction and vascular endothelium damage and that
EGCG protects cardiac myocytes from ischemia/reperfusion
injury also suggests that EGCG's cardioprotective effects
may be mediated by free radical scavenging. However, there
is little information about the effect of EGCG on cardiac
hypertrophy. Recently, we demonstrated that EGCG
inhibited platelet derived growth factor (PDGF)-BB-
induced intracellular Ca
2+ increase and extracellular signal-
regulated kinase (ERK) activation in vascular smooth
muscle cells (VSMCs) [1] and that EGCG could prevent
Ang II-induced VSMCs hypertrophy through blocking c-
Jun N-terminal kinases (JNKs) [29]. Moreover EGCG has
been shown to inhibit PI3K/Akt and Erk1/2 pathways in
several experimental models. These results suggest that
EGCG could inhibit the signal pathways that regulate
cardiac hypertrophy. Therefore, the purpose of this study is
to investigate whether chronic administration of an oral
daily dose of EGCG can attenuate cardiac hypertrophy
induced by pressure overload in rats.
Materials and Methods
In vivo hypertrophy model
Male Sprague Dawley rats (7 weeks old, 200-220 g) were
purchased from Koatech (Korea). The experimental protocol
was approved by the Chungbuk National University
Medical School Research Institutional Animal Care and Use
Committee. All surgical procedures were performed on
animals anesthetized with ketamine (80 mg/kg IP) and
xylazine (5 mg/kg IP). Abdominal aortic constriction (AC)
was performed using a 4-0 suture tied twice around the
suprarenal aorta and a 21-gauge needle. The needle was then
removed yielding a 0.8 mm internal diameter. Rats were
randomly assigned to AC or sham-operated groups and the
sham-operated rats underwent the same procedure, with the
exception that the aorta was not constricted. A freshly
prepared solution with different doses of EGCG (Sigma,
USA) was supplied every day to aortic banded or sham-
operated rats as the sole source of drinking water over a
period of 21 consecutive days, whereas control animals
were supplied with water from the same source, lacking
EGCG (Fig. 1). Dietary administration was chosen to
establish clinical relevance to human dietary habits.
Establishment of cardiac hypertrophy was confirmed by
echocardiography by measuring left ventricular (LV) wall
thickness and dimensions, heart weight, and by histological
analysis. The rats grew and gained weight during the course
of the study, and as a control, we measured heart weight
(HW) as a function of body weight (BW).
Hemodynamics measurements
Rat blood pressure was evaluated by direct cannulation of
the right carotid and left femoral artery. Mean arterial blood
pressure, heart rate and pressure gradient between carotid
and femoral arterial pressure were obtained from a pressure
transducer attached to each cannula, which was inserted
through a fluid-filled catheter. The values were recorded
using a computer data acquisition system (ML870; AD
Instrument, Australia) after blood pressure was stable for 10
min.
Histological analysis and cardiomyocyte size measurement
All hearts were arrested in diastole with KCl (30 mM),
followed by perfusion fixation with 10% paraformaldehyde.
Fixed hearts were embedded in paraffin, and 4 mm thick
sections were stained with hematoxylin and eosin for
assessing overall morphology. 
The surface area of a 2D silhouette of the myocyte was
estimated by measurement of the length and width at 20
different randomly chosen points from a cross section of the
LV free wall. Morphometric analysis was performed with i-
solution software (IMT, Korea). Our 2D surface area
(length × width, µm
2) is directly proportional to the surface
area of a cylinder (2π×radius × length). The extent of LV
fibrosis was measured using Cason’s trichrome staining.
Five sections of each heart were measured.
Echocardiography
After 21 days of aortic constriction, rats were anesthetized
with intraperitoneal pentobarbital (50 mg/kg), and cardiac
dimension and function were analyzed by 10-MHz pulse-
wave Doppler echocardiography (SONOACE 8800; Medison,
Korea). Two dimensionally guided M-mode of LV at the
papillary level was obtained from the parasternal long-axis
view. For each rat, measurements were made from at least 4
beats. LV cavity dimension and wall thickness were
measured, and percent change in LV dimension (fractional
shortening; FS) and relative wall thickness (RWT) were
Fig. 1. Experimental design. One day before the operation, rats
were randomly treated with EGCG or no drug. EGCG was
dissolved in drinking water and the administered solutions were
replaced every day for 3 weeks. Hemodynamic and morphologic
measurements were performed at for various time intervals afte r
abdominal aortic constriction (AC). Cardiac function was
measured after 8 weeks of AC.Epigallocatechin-3 gallate and myocardial hypertrophy 123
calculated as follows: FS = [(LVDd-LVSd)/LVDd] × 100,
where LVDd is LV dimension at end-diastole and LVSd is
LV dimension at end-systole. RWT = (posterior wall
thickness at end diastole)/ LVDd × 2.
Statistical analysis
Results are presented as mean ± SE. Data obtained were
compared using the unpaired Students t-test or one-way
ANOVA. Statistical significance was defined as a value of
p < 0.05.
Results
Effects of EGCG on load-induced increase in heart weight
The amount of water intake was measured every day.
Administration of EGCG in the drinking water at 0.02%,
0.04% and 0.08% did not alter water intake in either the
sham-operated or aortic constricted rats. AC induced a 48%
increase in HW/BW ratio compared to sham-operated rats.
EGCG administration completely attenuated this increase
(Fig. 2A). We found no significant difference between that
the effect of 0.04% EGCG on pressure overload induced
cardiac hypertrophy and that of 0.08% EGCG. The
estimated EGCG intake of rats fed with 0.04% EGCG
solution was 30 mg/kg. This estimate is based on an average
consumption of 200 ml/day. These results are comparable
with those in previous studies in which EGCG was non
toxic to the liver and other organs after rats were injected
intraperitoneally with 70-92 mg/kg daily [11]. Therefore, we
selected 0.04% as the experimental dose. EGCG did not
Fig. 2. Inhibition of pressure overload induced cardiac hypertrophy  in vivo by EGCG. A, Heart wet weight was normalized to body
weight in each rat as an index of cardiac hypertrophy. Heart weight to body weight ratio was attenuated in a dose-dependent man ner by
EGCG after 3 weeks of aortic constriction (AC). B, Liver weight to body weight ratio. 
#p < 0.001 compared with sham, n = 8; *p < 0.001
compared with AC, n ≥ 6. C, Representative hearts of rats treated with AC or AC + 0.04% EGCG for 3 weeks. scale = 1 mm.124 Jia Hao et al.
affect either body weight or liver weight (Fig. 2B). Next, we
examined the effect of EGCG on HW/BW at various time
intervals after AC surgery. During the 3 weeks after
constriction, HW/BW ratio was significantly increased. The
anti-hypertrophic effect of EGCG appeared as early as 1
week after surgery and was sustained during the course of
the study (Fig. 4).
Effects of ECGC on cardiac and myocyte morphometric
changes
Aortic constriction caused a significant increase in both
heart mass and LV wall thickness in comparison to sham-
operated rats. AC-induced cardiac enlargement was almost
completely prevented by EGCG, as shown in Fig. 2C. To
examine whether EGCG changed heart size through the
regulation of myocyte cell size, the myocyte cross-sectional
area of the LV myocardium was measured in hearts from
rats subjected to AC for 3 weeks (Fig. 3A & B). The cell
area of aortic constricted rats was increased by 28%
compared to sham-operated rats. This increase was almost
completely abrogated by EGCG administration. AC also
caused significant interstitial collagen deposition, as
demonstrated by Masson’s trichrome staining. This fibrosis
was reduced in AC rats treated with EGCG for 3 weeks
(Fig. 3C).
Effects of EGCG on hemodynamic loading conditions
Blockade of cardiac hypertrophy by EGCG in pressure-
overloaded rats raised the possibility that EGCG might
ameliorate the hypertension induced by AC, and thus the
Fig. 3. Effect of ECGC on myocyte cell area and cardiac fibrosis. A, heart tissues. H&E stain. bar = 50 µm. B, Cardiomyocyte cross
sectional area was decreased in the EGCG-treated group after 3 weeks of aortic constriction (AC). 
#p < 0.001 compared with sham,
*p < 0.001 compared with AC. C, Inhibition of perivascular fibrosis  in vivo by EGCG. Cason’s stain. bar = 200 µm.Epigallocatechin-3 gallate and myocardial hypertrophy 125
blockade of the hypertrophy might have been caused
secondarily by reduction of afterload rather than by a direct
cardiac effect. To rule out this possibility, blood pressure
was measured. As expected, aortic constriction markedly
increased the blood pressure and produced a large pressure
gradient between the carotid and femoral arteries. However,
EGCG did not affect the blood pressure, so that there was no
significant difference in pressure gradient between aortic-
banded rats and EGCG-treated aortic-banded rats (Table 1).
Thus, EGCG attenuated load-induced cardiac hypertrophy
in the presence of comparable hemodynamic loading
conditions.
Effect of EGCG on cardiac function of aortic constricted
rats
Eight weeks after constriction we examined the effect of
EGCG on cardiac function using echocardiography (Fig. 5).
Compared with sham-operated rats, aortic-banded rats
displayed a substantial increase in interventricular septum
thickness (IVSd) and LV posterior wall thickness in diastole
(PWT). RWT was also markedly increased from 0.32 ± 0.04
in the sham group to 0.58 ± 0.05 in the AC group, which
reveals evidence of concentric hypertrophy. Importantly,
EGCG treatment significantly decreased PWT and RWT.
EGCG-treated aortic-banded rats had a 20% increase in
cardiac contractility, assessed by fractional shortening,
compared to the AC group that did not receive EGCG
(Table 2).
Discussion
In the present study, we found that a daily oral dose of the
bioflavonoid EGCG can attenuate the cardiac hypertrophic
changes induced by pressure overload. In addition, we
showed that EGCG not only prevented cardiac hypertrophy
resulting from pressure overload, but also improved cardiac
performance mostly by reducing LV end diastolic and
systolic dimensions.
Sustained high blood pressure is one of the strongest
causes of the development of cardiac hypertrophy. EGCG
and related bioflavonoids have shown to have vasodilatory
effects probably induced both by facilitating diuretic
vasorelaxation and by evoking endothelial-dependent
vasorelaxation [14]. Likewise, it has been demonstrated that
EGCG has an anti-hypertensive effect in the 5/6 nephrectomy
rat model [20]. Therefore, blockage of pressure overload
induced cardiac hypertrophy by EGCG raised the possibility
that EGCG might ameliorate the hypertension induced by
AC surgery and that the blockage of hypertrophy might
have been secondary to afterload reduction rather than a
direct cardiac effect. In this study, AC produced a large
pressure gradient between carotid and femoral arteries; this
gradient was not affected by EGCG treatment (Table 1).
Hemodynamic measurements 3 weeks after surgery revealed
that EGCG had no significant effect on the transstenotic
aortic pressure gradients over time. By contrast, it has been
recently reported that EGCG administration attenuated the
increased blood pressure induced by aortic banding and
essentially blocked the development of cardiac hypertrophy
in this model [13]. The conflicting results from this study of
Li et al. [13] are probably due to the difference in the dose of
ECGC administered and the more severe banding
conditions. Although the beneficial effect of EGCG on
cardiovascular structure seems to be related to its blood
pressure lowering effect, it is unlikely that the reduction in
Table 1. Hemodynamic measurements at 3 weeks of pressure overload
Groups MAP
(mmHg)
DBP
(mmHg)
SBP
(mmHg)
Pressure gradient 
(between carotid and 
femoral artery)
Sham
AC
AC+EGCG
88.8 ± 3.3
130.2 ± 4.2*
135.0 ± 6.7*
81.2 ± 3.5
116.7 ± 3.8*
120.0 ± 5.5*
104.2 ± 2.90
157.2 ± 6.2*
0164.9 ± 10.0*
5.6 ± 1.5
33.0 ± 6.4*
31.2 ± 5.6*
Data are mean ± SE; n ≥ 8. AC, aortic constriction; MAP, mean arterial pressure; DBP, diastolic blood pressure; SBP, systolic blood pressure.
*p < 0.001 compared with sham.
Fig. 4. Inhibition of cardiac hypertrophy in vivo by EGCG at
various time intervals with pressure overload. 
#p < 0.05 compared
with sham, *p < 0.001 compared with AC (n ≥ 11).126 Jia Hao et al.
cardiac hypertrophy seen with this lower dose of EGCG was
caused by relief of pressure overload. Our data suggests that
the primary target organ of EGCG is the heart rather than
blood vessels.
Previous reports that EGCG induced apoptosis of tumor
cells raise the possibility that apoptosis in cardiomyocytes
may occur in our animal model, leading to a reduction in
cardiac mass. We did not perform the TUNEL assay in this
study but it has been previously reported that pressure
overload itself leads to an
  increase in TUNEL-positive
cardiomyocytes [26]. Moreover, EGCG does not significantly
affect the survival of cultured rat cardiomyocytes and has
even been shown to have a protective effect against
apoptosis induced by ischemic reperfusion injury [23].
Although EGCG has proapoptotic effects in transformed
cells, apoptosis of cardiomyocytes does not appear to be
responsible for the reduction of heart mass.
Pressure overload induces LV hypertrophy as a
compensatory response to increased wall stress. This has
been considered
 the central mechanism by which cardiac
function is maintained within normal ranges in chronically
overloaded hearts. Accordingly, suppression
 of myocardial
hypertrophy is expected to cause heart failure.
 However, it
has been suggested that under conditions of pressure
overload, the development of cardiac hypertrophy and
normalization of wall stress may not be a required
compensatory response to pressure overload and may not be
necessary to preserve cardiac function. Recently, it has been
demonstrated that using genetically engineered mice that
have markedly blunted growth responses to pressure
overload, cardiac function was well maintained after loading
(using a partial aortic constriction), despite the failure to
correct wall stress. Indeed, function was in fact better
maintained than in wild-type mice, in which hypertrophy
ensued [6]. Moreover, Hill et al. [8] reported preserved
cardiac output without hypertrophic compensation in the
setting of pressure overload in thoracic aortic banding mice
treated with cyclosporine A.
In this study, we examined the effect of EGCG on cardiac
function using echocardiography. Treatment with EGCG
greatly attenuated cardiac hypertrophy and there was no
detectable impairment
 of cardiac function for 3 weeks. This
result suggests that treatment with EGCG allowed the heart
to adapt to pressure
 overload, even in the absence of LV
hypertrophy.
Maintenance of cardiac output in the face of increased
afterload without sufficient LV hypertrophy implies a
positive inotropic effect. It has been known that under some
experimental conditions, an increase in afterload causes an
increase in ventricular inotropy. This homeometric
autoregulation is called the Anrep effect [25]. Increased
inotropy partially compensates for the increased end-
systolic volume and decreased stroke volume caused by an
increase in afterload. In this study, EGCG-treated aortic-
Fig. 5. Representative M-mode echocardiograms after 8 weeks of aortic constriction (AC). Quantitative data are shown in Table 2.
Concentric cardiac remodeling was observed in the AC group.
Table 2. Echocardiographic changes after pressure overload
2 weeks 4 weeks 8 weeks
Sham AC AC+EGCG Sham AC AC+EGCG Sham AC AC+EGCG
IVSd (mm) 01.55±0.30 01.87±0.06*01.63±0.09
† 01.55±0.15 01.75±0.14*01.60±0.14
† 001.6±0.12 01.88±0.17*01.63±0.20
†
LVISd (mm) 04.55±0.95 04.42±0.36 004.6±0.21 04.25±0.05 005.6±0.28*005.4±0.46 004.8±0.20 005.8±0.37*005.7±0.38
†
LVIDd (mm) 06.95±0.15 06.82±0.29 06.73±0.21 06.90±0.20 07.35±0.17*07.63±0.32 007.8±0.11 07.68±0.29 08.05±0.34
†
PWTd (mm) 001.3±0.10 01.78±0.12*01.65±0.13
† 01.25±0.10 02.08±0.19*01.53±0.20
† 01.25±0.10 02.20±0.11*01.65±0.21
†
RWT (mm/mm) 00.37±0.04 00.54±0.06*00.50±0.07* 00.36±0.01 00.57±0.07*00.40±0.06
† 00.32±0.04 00.58±0.05*00.42±0.07
†
FS (%) 34.53±12.3 35.21±2.5 31.60±1.9 38.41±2.5 23.81±2.7* 29.18±4.0
† 33.33±0.6 24.43±2.2* 29.19±2.3
†
Data are mean ± SE; n ≥ 6. AC, aortic constriction; IVSd, interventricular septum thickness; LVISd, Left ventricular systolic diameter; LVIDd, Left
ventricular diastolic diameter; PWTd, posterior wall thickness of the left ventricle in diastole, respectively; RWT, relative w all thickness; FS, fractional
shortening. * p < 0.05 compared with the sham; 
†p < 0.05 compared to the AC.Epigallocatechin-3 gallate and myocardial hypertrophy 127
banded rats had increased LV diastolic dimensions after 4
weeks. We presume that the Anrep effect in the EGCG-
treated aortic-banded rat heart, which is under sustained
pressure overload, was gradually exhausted, whereas
cardiac function is still maintained. Additional work will be
necessary to test this hypothesis and to evaluate the long-
term effects of EGCG on cardiac function and survival in
aortic constricted rats.
Reactive oxygen species (ROS) have been shown in a
variety of cell
  types to act as intracellular signaling
molecules in the stress response, leading to apoptosis,
proliferation, and transformation. In cardiomyocytes, ROS
have been found to be involved in cardiac hypertrophy in
vitro [22] and to mediate hypertrophy induced by several
stimuli, such as mechanical stretch [19], Ang II [16], and
tumor necrosis factor-α [7]. EGCG has been known to have
potent antioxidant activity [15]. We found that the levels of
malondialdehyde (MDA) were markedly increased in the
AC group and EGCG treatment resulted in an almost
complete elimination of the increase in MDA (data not
shown). Therefore, we propose that the antioxidant effect
might also play a role in the prevention of cardiac
hypertrophy in AC rats treated with EGCG.
A different location of the aortic constriction may
differently activate the signal transduction pathway. When
the aortic arch was constricted, mechanical force may have
been the major cause of cardiac hypertrophy. In contrast, the
renin-angiotensin system (RAS) may be involved
predominantly in suprarenal abdominal aorta constriction
and contribute to the initial development of cardiac
hypertrophy and sympathetic activation in the compensated
heart. It has been shown that losartan, an Ang II AT 1
receptor antagonist, attenuates cardiac hypertrophy in
suprarenal abdominal aorta constricted rat [12], but has no
effect on the weight gain of the ventricle during aortic arch
constriction [2]. Given that EGCG can inhibit Ang II
mediated signal transduction in cultured cardiomyocytes
[28], the antihypertrophic effect of EGCG in the present
study could have been mediated by RAS blockage.
However, EGCG had no significant effect on systemic
blood pressure, which sensitive to Ang II. These findings
suggest that inhibition of RAS by EGCG does not play a
major role in the EGCG-mediated antihypertrophic effect.
Calcineurin inhibitors, such as cyclosporine A and FK506
have been well known to inhibit cardiac hypertrophy.
However, nephrotoxicity and the immunosuppressive effect
of calcineurin inhibitors limit their therapeutic benefit [24].
In our experiment, EGCG completely inhibited cardiac
hypertrophy induced by pressure overload without
significant effects on normal heart and liver. There was no
evidence of nonspecific toxicity since no effects on normal
growth, weight gain, or physical activity were found.
Therefore, EGCG, or its derivatives, might be a useful
modality to suppress cardiac hypertrophy.
In congestive heart failure by concentric hypertrophy,
positive inotropic agents may significantly reduce
intraventricular volume and cardiac output and thus
contribute to a increase in mortality, so positive inotropes are
prohibited in the treatment of concentric hypertrophy. Hotta
et al. [9] showed that EGCG (10
−6, 10
−5 M) increased LV
developed pressure and claimed that EGCG represents a
positive inotropic effect via the nitric oxide pathway [9].
Given the low bioavailability of EGCG, it is unlikely that
EGCG had an inotropic effect in our experimental system.
In this study, we demonstrated that EGCG (approximately
30 mg EGCG/kg body weight) prevents the development of
cardiac hypertrophy induced by pressure overload. It has
been reported that most of the EGCG does not get into the
blood, but is excreted through the bile to the colon, so that
serum concentration of total EGCG was 43 nM in male rats
treated with 75 mg EGCG/kg body weight by gavage [3].
Even if such a low dose of EGCG had a positive inotropic
effect, this effect partially compensated for the increase in
afterload and helped the heart to adapt to pressure overload
at the development of hypertrophy stage. However, we can
not exclude the possibility that EGCG would have a harmful
effect on advanced chronic heart failure and a severely
dilated ventricle. Future studies are necessary to examine
whether EGCG can regress established cardiac hypertrophy,
which might be of greater clinical significance because the
patient
 would most likely already have hypertrophy at the
initiation of treatment.
In conclusion, this study demonstrates that EGCG
completely inhibited cardiac hypertrophy and improved
cardiac performance in pressure overloaded hearts. These
findings may have important clinical implications in
developing new therapeutic strategies to prevent the
transition from cardiac hypertrophy to heart failure.
Acknowledgments
This study was supported by grants from Chungbuk
National University (2005) and the Research Center for
Bioresource and Health and Sama Pharmaceutical Co.,
Korea.
References
1. Ahn HY, Hadizadeh KR, Seul C, Yun YP, Vetter H,
Sachinidis A. Epigallocathechin-3 gallate selectively inhibits
the PDGF-BB-induced intracellular signaling transduction
pathway in vascular smooth muscle cells and inhibits
transformation of sis-transfected NIH 3T3 fibroblasts and
human glioblastoma cells (A172). Mol Biol Cell 1999,  10,
1093-1104.
2. Baba HA, Iwai T, Bauer M, Irlbeck M, Schmid KW,
Zimmer HG. Differential effects of angiotensin II receptor
blockade on pressure-induced left ventricular hypertrophy
and fibrosis in rats. J Mol Cell Cardiol 1999, 31, 445-455.128 Jia Hao et al.
3. Chen L, Lee MJ, Li H, Yang CS. Absorption, distribution,
elimination of tea polyphenols in rats. Drug Metab Dispos
1997, 25, 1045-1050.
4. Chyu KY, Babbidge SM, Zhao X, Dandillaya R, Rietveld
AG, Yano J, Dimayuga P, Cercek B, Shah PK. Differential
effects of green tea-derived catechin on developing versus
established atherosclerosis in apolipoprotein E-null mice.
Circulation 2004, 109, 2448-2453.
5. Duarte J, Perez-Vizcaino F, Utrilla P, Jimenez J, Tamargo
J, Zarzuelo A. Vasodilatory effects of flavonoids in rat aortic
smooth muscle. Structure-activity relationships. Gen
Pharmacol 1993, 24, 857-862.
6. Esposito G, Rapacciuolo A, Naga Prasad SV, Takaoka H,
Thomas SA, Koch WJ, Rockman HA. Genetic alterations
that inhibit in vivo pressure-overload hypertrophy prevent
cardiac dysfunction despite increased wall stress. Circulation
2002, 105, 85-92.
7. Higuchi Y, Otsu K, Nishida K, Hirotani S, Nakayama H,
Yamaguchi O, Matsumura Y, Ueno H, Tada M, Hori M.
Involvement of reactive oxygen species-mediated NF-κB
activation in TNF-α-induced cardiomyocyte hypertrophy. J
Mol Cell Cardiol 2002, 34, 233-240.
8. Hill JA, Karimi M, Kutschke W, Davisson RL,
Zimmerman K, Wang Z, Kerber RE, Weiss RM. Cardiac
hypertrophy is not a required compensatory response to
short-term pressure overload. Circulation 2000, 101, 2863-
2869. 
9. H o t t a  Y ,  H u a n g  L ,  M u t o  T ,  Y a j i m a  M ,  M i y a z e k i  K ,
Ishikawa N, Fukuzawa Y, Wakida Y, Tushima H, Ando
H, Nonogaki T. Positive inotropic effect of purified green tea
catechin derivative in guinea pig hearts: the measurements of
cellular Ca2+ and nitric oxide release. Eur J Pharmacol 2006,
552, 123-130.
10. Jeong WS, Kim IW, Hu R, Kong AN. Modulatory
properties of various natural chemopreventive agents on the
activation of NF-κB signaling pathway. Pharm Res 2004, 21,
661-670.
11. Kao YH, Hiipakka RA, Liao S. Modulation of endocrine
systems and food intake by green tea epigallocatechin
gallate. Endocrinology 2000, 141, 980-987.
12. Li J, Li P, Feng X, Li Z, Hou R, Han C, Zhang Y. Effects
of losartan on pressure overload-induced cardiac gene
expression profiling in rats. Clin Exp Pharmacol Physiol
2003, 30, 827-832.
13. Li HL, Huang Y, Zhang CN, Liu G, Wei YS, Wang AB,
Liu YQ, Hui RT, Wei C, Williams GM, Liu DP, Liang
CC. Epigallocatechin-3 gallate inhibits cardiac hypertrophy
through blocking reactive oxidative species-dependent and -
independent signal pathways. Free Radic Biol Med 2006, 40,
1756-1775.
14. Lorenz M, Wessler S, Follmann E, Michaelis W,
Dusterhoft T, Baumann G, Stangl K, Stangl V.  A
constituent of green tea, epigallocatechin-3-gallate, activates
endothelial nitric oxide synthase by a phosphatidylinositol-3-
OH-kinase-, cAMP-dependent protein kinase-, and Akt-
dependent pathway and leads to endothelial-dependent
vasorelaxation. J Biol Chem 2004, 279, 6190-6195.
15. Nagai K, Jiang MH, Hada J, Nagata T, Yajima Y,
Yamamoto S, Nishizaki T. (-)-Epigallocatechin gallate
protects against NO stress-induced neuronal damage after
ischemia by acting as an anti-oxidant. Brain Res 2002,  956,
319-322.
16. Nakamura K, Fushimi K, Kouchi H, Mihara K, Miyazaki
M, Ohe T, Namba M. Inhibitory effects of antioxidants on
neonatal rat cardiac myocyte hypertrophy induced by tumor
necrosis factor-α and angiotensin II. Circulation 1998, 98,
794-799.
17. Mosterd A, Hoes AW, de Bruyne MC, Deckers JW,
Linker DT, Hofman A, Grobbee DE. Prevalence of heart
failure and left ventricular dysfunction in the general
population; The Rotterdam Study. Eur Heart J 1999, 20, 447-
455.
18. Murray CJ, Lopez AD. Mortality by cause for eight regions
of the world: Global Burden of Disease Study. Lancet 1997,
349, 1269-1276.
19. P i m e n t e l  D R ,  A m i n  J K ,  X i a o  L ,  M i l l e r  T ,  V i e r e c k  J ,
Oliver-Krasinski J, Baliga R, Wang J, Siwik DA, Singh
K, Pagano P, Colucci WS, Sawyer DB. Reactive oxygen
species mediate amplitude-dependent hypertrophic and
apoptotic responses to mechanical stretch in cardiac
myocytes. Circ Res 2001, 89, 453-460. 
20. Priyadarshi S, Valentine B, Han C, Fedorova OV, Bagrov
AY, Liu J, Periyasamy SM, Kennedy D, Malhotra D, Xie
Z, Shapiro JI. Effect of green tea extract on cardiac
hypertrophy following 5/6 nephrectomy in the rat. Kidney Int
2003, 63, 1785-1790.
21. Ruwhof C, van der Laarse A. Mechanical stress-induced
cardiac hypertrophy: mechanisms and signal transduction
pathways. Cardiovasc Res 2000, 47, 23-37.
22. Siwik DA, Tzortzis JD, Pimental DR, Chang DL, Pagano
PJ, Singh K, Sawyer DB, and Colucci WS. Inhibition of
copper-zinc superoxide dismutase induces cell growth,
hypertrophic phenotype, and apoptosis in neonatal rat cardiac
myocytes in vitro. Circ Res 1999, 85, 147-153. 
23. Townsend PA, Scarabelli TM, Pasini E, Gitti G,
Menegazzi M, Suzuki H, Knight RA, Latchman DS,
Stephanou A. Epigallocatechin-3-gallate inhibits STAT-1
activation and protects cardiac myocytes from ischemia/
reperfusion-induced apoptosis. FASEB J 2004, 18,1621-
1623.
24. Ventura HO, Malik FS, Mehra MR, Stapleton DD, Smart
FW. Mechanisms of hypertension in cardiac transplantation
and the role of cyclosporine. Curr Opin Cardiol 1997, 12,
375-381.
25. von Anrep G. On the part played by the suprarenals in the
normal vascular reactions of the body. J Physiol 1912, 45,
307-317.
26. Yamaguchi O, Higuchi Y, Hirotani S, Kashiwase K,
Nakayama H, Hikoso S, Takeda T, Watanabe T, Asahi M,
Taniike M, Matsumura Y, Tsujimoto I, Hongo K,
Kusakari Y , Kurihara S, Nishida K, Ichijo H, Hori M,
Otsu K. Targeted deletion of apoptosis signal-regulating
kinase 1 attenuates left ventricular remodeling. Proc Natl
Acad Sci USA 2003, 100, 15883-15888.
27. Yue TL, Gu JL, Wang C, Reith AD, Lee JC, Mirabile RC,
Kreutz R, Wang Y, Maleeff B, Parsons AA, Ohlstein EH.Epigallocatechin-3 gallate and myocardial hypertrophy 129
Extracellular signal-regulated kinase plays an essential role
in hypertrophic agonists, endothelin-1 and phenylephrine-
induced cardiomyocyte hypertrophy. J Biol Chem 2000, 275,
37895-37901.
28. Zheng Y, Song HJ, Kim CH, Kim HS, Kim EG,
Sachinidis A, Ahn HY. Inhibitory effect of epigallocatechin
3-O-gallate on vascular smooth muscle cell hypertrophy
induced by angiotensin II. J Cardiovasc Pharmacol 2004, 43,
200-208.
29. Zou Y, Komuro I, Yamazaki T, Kudoh S, Aikawa R, Zhu
W, Shiojima I, Hiroi Y, Tobe K, Kadowaki T, Yazaki Y.
Cell type-specific angiotensin II-evoked signal transduction
pathways: critical roles of G βγ subunit, Src family, and Ras in
cardiac fibroblasts. Circ Res 1998, 82, 337-345.